Adc Therapeutics Sa (ADCT)

$4.01

+0.19

(+4.97%)

Market is closed - opens 7 PM, 16 Jul 2024

Performance

  • $3.74
    $4.01
    $4.01
    downward going graph

    6.73%

    Downside

    Day's Volatility :6.73%

    Upside

    0.0%

    downward going graph
  • $0.36
    $6.04
    $4.01
    downward going graph

    91.02%

    Downside

    52 Weeks Volatility :94.04%

    Upside

    33.61%

    downward going graph

Returns

PeriodAdc Therapeutics SaSector (Health Care)Index (Russel 2000)
3 Months
-12.59%
6.9%
0.0%
6 Months
103.19%
6.1%
0.0%
1 Year
143.31%
12.6%
0.0%
3 Years
-83.19%
15.3%
-18.2%

Highlights

Market Capitalization
303.1M
Book Value
- $2.35
Earnings Per Share (EPS)
-2.77
Wall Street Target Price
10.0
Profit Margin
0.0%
Operating Margin TTM
-186.19%
Return On Assets TTM
-24.08%
Return On Equity TTM
-705.53%
Revenue TTM
68.6M
Revenue Per Share TTM
0.84
Quarterly Revenue Growth YOY
-4.9%
Gross Profit TTM
35.1M
EBITDA
-148.1M
Diluted Eps TTM
-2.77
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.89
EPS Estimate Next Year
-1.58
EPS Estimate Current Quarter
-0.56
EPS Estimate Next Quarter
-0.55

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Adc Therapeutics Sa(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 149.38%

Current $4.01
Target $10.00

Company Financials

FY21Y/Y Change
Revenue
33.9M
↑ 0.0%
Net Income
-230.0M
↑ 0.0%
Net Profit Margin
-678.2%
↑ 0.0%
FY21Y/Y Change
Revenue
33.9M
↑ 0.0%
Net Income
-230.0M
↑ 0.0%
Net Profit Margin
-678.2%
↑ 0.0%
FY22Y/Y Change
Revenue
209.9M
↑ 0.0%
Net Income
-155.8M
↑ 0.0%
Net Profit Margin
-74.22%
↑ 0.0%
FY22Y/Y Change
Revenue
209.9M
↑ 0.0%
Net Income
-155.8M
↑ 0.0%
Net Profit Margin
-74.22%
↑ 0.0%
FY23Y/Y Change
Revenue
69.6M
↑ 0.0%
Net Income
-240.1M
↑ 0.0%
Net Profit Margin
-345.11%
↑ 0.0%
FY23Y/Y Change
Revenue
69.6M
↑ 0.0%
Net Income
-240.1M
↑ 0.0%
Net Profit Margin
-345.11%
↑ 0.0%
Q4 FY22Q/Q Change
Revenue
69.8M
↓ 8.55%
Net Income
-24.2M
↓ 52.27%
Net Profit Margin
-34.61%
↑ 31.7%
Q1 FY23Q/Q Change
Revenue
19.0M
↓ 72.79%
Net Income
-59.4M
↑ 146.0%
Net Profit Margin
-312.9%
↓ 278.29%
Q2 FY23Q/Q Change
Revenue
19.3M
↑ 1.53%
Net Income
-47.1M
↓ 20.71%
Net Profit Margin
-244.34%
↑ 68.56%
Q3 FY23Q/Q Change
Revenue
14.5M
↓ 24.84%
Net Income
-47.8M
↑ 1.46%
Net Profit Margin
-329.86%
↓ 85.52%
Q4 FY23Q/Q Change
Revenue
16.8M
↑ 15.85%
Net Income
-85.0M
↑ 77.86%
Net Profit Margin
-506.44%
↓ 176.58%
Q1 FY24Q/Q Change
Revenue
18.1M
↑ 7.52%
Net Income
-46.6M
↓ 45.19%
Net Profit Margin
-258.16%
↑ 248.28%
FY21Y/Y Change
Total Assets
618.0M
↑ 0.0%
Total Liabilities
451.9M
↑ 0.0%
FY21Y/Y Change
Total Assets
618.0M
↑ 0.0%
Total Liabilities
451.9M
↑ 0.0%
FY22Y/Y Change
Total Assets
529.2M
↑ 0.0%
Total Liabilities
440.4M
↑ 0.0%
FY22Y/Y Change
Total Assets
529.2M
↑ 0.0%
Total Liabilities
440.4M
↑ 0.0%
FY23Y/Y Change
Total Assets
354.8M
↑ 0.0%
Total Liabilities
503.0M
↑ 0.0%
FY23Y/Y Change
Total Assets
354.8M
↑ 0.0%
Total Liabilities
503.0M
↑ 0.0%
Q4 FY22Q/Q Change
Total Assets
529.2M
↓ 0.49%
Total Liabilities
440.4M
↑ 3.15%
Q1 FY23Q/Q Change
Total Assets
467.7M
↓ 11.62%
Total Liabilities
430.0M
↓ 2.37%
Q2 FY23Q/Q Change
Total Assets
507.3M
↑ 8.47%
Total Liabilities
515.9M
↑ 19.98%
Q3 FY23Q/Q Change
Total Assets
466.9M
↓ 7.96%
Total Liabilities
521.1M
↑ 1.01%
Q4 FY23Q/Q Change
Total Assets
354.8M
↓ 24.01%
Total Liabilities
503.0M
↓ 3.46%
Q1 FY24Q/Q Change
Total Assets
308.0M
↓ 13.2%
Total Liabilities
502.4M
↓ 0.12%
FY21Y/Y Change
Operating Cash Flow
-233.4M
↑ 0.0%
Investing Cash Flow
-6.7M
↑ 0.0%
Financing Cash Flow
267.4M
↑ 0.0%
FY21Y/Y Change
Operating Cash Flow
-233.4M
↑ 0.0%
Investing Cash Flow
-6.7M
↑ 0.0%
Financing Cash Flow
267.4M
↑ 0.0%
FY22Y/Y Change
Operating Cash Flow
-136.8M
↑ 0.0%
Investing Cash Flow
-2.5M
↑ 0.0%
Financing Cash Flow
-593.0K
↑ 0.0%
FY22Y/Y Change
Operating Cash Flow
-136.8M
↑ 0.0%
Investing Cash Flow
-2.5M
↑ 0.0%
Financing Cash Flow
-593.0K
↑ 0.0%
Q4 FY22Q/Q Change
Operating Cash Flow
-52.1M
↓ 2473.44%
Investing Cash Flow
-117.0K
↓ 53.94%
Financing Cash Flow
-2.4M
↓ 203.51%
Q1 FY23Q/Q Change
Operating Cash Flow
-14.8M
↓ 71.65%
Investing Cash Flow
-661.0K
↑ 464.96%
Financing Cash Flow
-196.0K
↓ 91.99%
Q2 FY23Q/Q Change
Operating Cash Flow
-36.8M
↑ 149.31%
Investing Cash Flow
-661.0K
↑ 0.0%
Financing Cash Flow
74.7M
↓ 38232.14%
Q3 FY23Q/Q Change
Operating Cash Flow
-34.0M
↓ 7.63%
Investing Cash Flow
-661.0K
↑ 0.0%
Financing Cash Flow
-2.3M
↓ 103.09%

Technicals Summary

Sell

Neutral

Buy

Adc Therapeutics Sa is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Adc Therapeutics Sa
Adc Therapeutics Sa
35.46%
103.19%
143.31%
-83.19%
-87.12%
Moderna, Inc.
Moderna, Inc.
-11.92%
18.89%
-0.93%
-53.23%
748.18%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.23%
17.36%
52.44%
86.66%
268.9%
Novo Nordisk A/s
Novo Nordisk A/s
1.22%
33.6%
76.55%
224.35%
496.35%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.18%
11.71%
36.53%
144.26%
177.11%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Adc Therapeutics Sa
Adc Therapeutics Sa
NA
NA
NA
-1.89
-7.06
-0.24
NA
-2.35
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Adc Therapeutics Sa
Adc Therapeutics Sa
Buy
$303.1M
-87.12%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
748.18%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
268.9%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
496.35%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
177.11%
31.94
39.46%

Insights on Adc Therapeutics Sa

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 14.49M → 18.05M (in $), with an average increase of 10.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -85.03M → -46.60M (in $), with an average increase of 82.5% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 220.5% return, outperforming this stock by 303.7%

Institutional Holdings

  • Redmile Group, LLC

    15.87%
  • Prosight Management, LP

    7.33%
  • Morgan Stanley - Brokerage Accounts

    2.83%
  • Goldman Sachs Group Inc

    1.60%
  • Bank of America Corp

    1.24%
  • Millennium Management LLC

    1.05%

Company Information

adc therapeutics is a biotechnology company located in lausanne, vaud, switzerland.

Organization
Adc Therapeutics Sa
Employees
273
CEO
Dr. Ameet Mallik M.B.A., M.S.
Industry
Health Technology

FAQs